Vega Bioimaging Technologies Inc

Vega BioImaging | The Future of Quantitative Immunolabeling At Vega BioImaging, we are revolutionizing cancer diagnostics and drug development with next-generation plasmonic nanotechnology. Our patented nanobead-based immunolabeling technology delivers fully quantitative, multiplexed, and objective biomarker analysis—transforming the accuracy and reproducibility of tissue diagnostics. A New Standard in Biomarker Detection Our technology addresses the 7-30% error rate in histopathological classification, ensuring precise patient selection for targeted therapies and clinical trials. By eliminating subjectivity in immunohistochemistry (IHC) and enhancing biomarker quantification, we empower researchers, pathologists, and pharmaceutical companies to accelerate drug development and improve treatment outcomes. Fully Compatible & Scalable Vega’s solutions integrate seamlessly into existing workflows, requiring no fluorescence or darkroom setups. Our approach is designed for diagnostic labs, biotech firms, and pharmaceutical companies seeking reliable, scalable solutions for companion diagnostics (CDx) and research applications. Advancing Cancer Research & Drug Development We offer a broad portfolio of imaging solutions to visualize plasmonic nanoparticles in tissue and cell analysis. Our long-term vision is to revolutionize cytopathology and biomarker quantification, enabling early cancer detection and precision medicine. Join the Future of Immunolabeling We partner with biotech, pharma, and clinical researchers to push the boundaries of diagnostics and personalized medicine. Connect with us to explore how Vega BioImaging can help improve biomarker assessment, enhance drug development pipelines, and optimize patient outcomes.